Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 1/2014

Open Access 01-12-2014 | Research article

Systematic review and meta-analysis of the proportion of Campylobacter cases that develop chronic sequelae

Authors: Jessica Keithlin, Jan Sargeant, M Kate Thomas, Aamir Fazil

Published in: BMC Public Health | Issue 1/2014

Login to get access

Abstract

Background

Understanding of chronic sequelae development after Campylobacter infection is limited. The objective of the study was to determine via systematic review and meta-analysis the proportion of Campylobacter cases that develop chronic sequelae.

Methods

A systematic review of English language articles published prior to July 2011 located using Pubmed, Agricola, CabDirect, and Food Safety and Technology Abstracts. Observational studies reporting the number of Campylobacter cases that developed reactive arthritis (ReA), Reiter’s syndrome (RS), haemolytic uraemic syndrome (HUS), irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) ,Guillain Barré syndrome (GBS) or Miller Fisher syndrome (MFS) were included. Data extraction through independent extraction of articles by four reviewers (two per article). Random effects meta-analysis was performed and heterogeneity was assessed using the I2 value. Meta-regression was used to explore the influence of study level variables on heterogeneity.

Results

A total of 31 studies were identified; 20 reported on ReA, 2 reported on RS, 9 reported on IBS, 3 studies reported on IBD, 8 reported on GBS, 1 reported on MFS and 3 reported on HUS. The proportion of Campylobacter cases that developed ReA was 2.86% (95% CI 1.40% - 5.61%, I2 = 97.7%), irritable bowel syndrome was 4.01% (95% CI 1.41% - 10.88%, I2 = 99.2%). Guillain Barré syndrome was 0.07% (95% CI 0.03% - 0.15%, I2 = 72.7%).

Conclusions

A significant number of Campylobacter cases develop a chronic sequela. However, results should be interpreted with caution due to the high heterogeneity.
Appendix
Available only for authorised users
Literature
1.
Scallan E, Hoekstra RM, Angulo FG, Tauxe RV, Widdowson MA, Roy SL, Jones JL, Griffin PM: Foodborne illness acquired in the United States - major pathogens. Emerg Infect Dis. 2011, 17: 7-10.3201/eid1701.P11101.CrossRefPubMedPubMedCentral
2.
Government of Canada: Canadian Notifiable Disease Surveillance System National Report (2005–2008). 2012, Canada: Public Health Agency of Canada
3.
Thomas MK, Majowicz SE, Sockett PN, Fazil A, Pollari F, Doré K, Flint JA, Edge VL: Estimated numbers of community cases of illness due to Salmonella, Campylobacter and verotoxigenic Escherichia coli: Pathogen-specific community rates. Can J Infect Dis Med Microbiol. 2006, 17: 229-234.PubMedPubMedCentral
4.
Smith JL: Campylobacter jejuni infection during pregnancy: Long-term consequences of associated bacteremia, Guillain-Barré syndrome, and reactive arthritis. J Food Prot. 2002, 65: 696-708.PubMed
5.
6.
Abley MJ, Wittum TE, Funk JA, Gebreyes WA: Antimicrobial susceptibility, pulsed-field gel electrophoresis, and multi-locus sequence typing of Campylobacter coli in swine before, during, and after the slaughter process. Foodborne Pathog Dis. 2012, 9: 506-512. 10.1089/fpd.2011.1053.CrossRefPubMed
7.
Hermans D, Pasmans F, Messens W, Martel A, Van Immerseel F, Rasschaert G, Heyndrickx M, Van Deun K, Haesebrouck F: Poultry as a host for the zoonotic pathogen Campylobacter jejuni. Vector Borne Zoonotic Dis. 2012, 12: 89-98. 10.1089/vbz.2011.0676.CrossRefPubMed
8.
Domingues AR, Pires SM, Halasa T, Hald T: Source attribution of human campylobacteriosis using a meta-analysis of case–control studies of sporadic infections. Epidemiol Infect. 2012, 140: 970-981. 10.1017/S0950268811002676.CrossRefPubMed
9.
Kwong JC, Crowcroft NS, Campitelli MA, Ratnasingham S, Daneman N, Deeks SL, Manuel DG: Ontario burden of infectious disease study (ONBOIDS): An OAHPP/ICES report. 2010, Toronto: Ontario Agency for Health Protection and Promotion, Institute for Clinical Evaluative Sciences
10.
Havelaar AH, Haagsma JA, Mangen MJ, Kemmeren JM, Verhoef LP, Vijgen SM, Wilson M, Friesema IH, Kortbeek LM, van Duynhoven YT, van Pelt W: Disease burden of foodborne pathogens in the Netherlands, 2009. Int J Food Microbiol. 2012, 156: 231-238. 10.1016/j.ijfoodmicro.2012.03.029.CrossRefPubMed
11.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analysis of studies that evaluate health care interventions. Br Med J. 2009, 6: 1-28.CrossRef
12.
Higgins JPT, Green S: Cochrane handbook for systematic reviews of interventions version 5.1.0. Cochrane Collaboration. 2011, 5: 1-
13.
Thabane M, Kottachchi DT, Marshall JK: Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther. 2007, 26: 535-544. 10.1111/j.1365-2036.2007.03399.x.CrossRefPubMed
14.
Karlinger K, Gyorke T, Mako E, Mester A, Tarján Z: The epidemiology and the pathogenesis of inflammatory bowel disease. Eur J Radiol. 2000, 35: 154-167. 10.1016/S0720-048X(00)00238-2.CrossRefPubMed
15.
Israeli E, Agmon-Levin N, Blank M, Chapman J, Shoenfeld Y: Guillain-Barré syndrome–a classical autoimmune disease triggered by infection or vaccination. Clin Rev Allergy Immunol. 2012, 42: 121-130. 10.1007/s12016-010-8213-3.CrossRefPubMed
16.
Nachamkin I, Allos BM, Ho T: Campylobacter species and Guillain-Barré syndrome. Clin Microbiol Rev. 1998, 11: 555-567.PubMedPubMedCentral
17.
Pope JE, Krizova A, Garg AX, Thiessen-Philbrook H, Ouimet JM: Campylobacter reactive arthritis: A systematic review. Semin Arthritis Rheum. 2007, 37: 48-55. 10.1016/j.semarthrit.2006.12.006.CrossRefPubMedPubMedCentral
18.
Poropatich KO, Walker CL, Black RE: Quantifying the association between Campylobacter infection and Guillain-Barré syndrome: A systematic review. J Health Popul Nutr. 2010, 28: 545-552.CrossRefPubMedPubMedCentral
19.
Riddle MS, Gutierrez RL, Verdu EF, Porter CK: The chronic gastrointestinal consequences associated with Campylobacter. Curr Gastroenterol Rep. 2012, 14: 395-405. 10.1007/s11894-012-0278-0.CrossRefPubMed
20.
Sanchez J, Dohoo IR, Christensen J, Rajic A: Factors influencing the prevalence of Salmonella spp. in swine farms: A meta-analysis approach. Prev Vet Med. 2007, 81: 148-177. 10.1016/j.prevetmed.2007.04.005.CrossRefPubMed
21.
Egger M, Smith D, Altmand DG: Systematic reviews in health care: Meta-analysis in context. 2001, London: BMJ Publishing Group, 2CrossRef
22.
Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med. 2002, 21: 1539-1558. 10.1002/sim.1186.CrossRefPubMed
23.
Pitkanen T, Pettersson T, Ponka A, Kosunen TU: Clinical and serological studies in patients with Campylobacter fetus/ssp/jejuni infection: clinical findings. Infection. 1981, 9: 274-278. 10.1007/BF01640990.CrossRefPubMed
24.
Wang SC, Chang LY, Hsueh PR, Lu CY, Lee PI, Shao PL, Hsieh YC, Yen FP, Lee CY, Huang LM: Campylobacter enteritis in children in northern Taiwan–a 7-year experience. J Microbiol Immunol Infect. 2008, 41: 408-413.PubMed
25.
26.
Rowe PC, Walop W, Lior H, Mackenzie AM: Haemolytic anaemia after childhood Escherichia coli O 157.H7 infection: Are females at increased risk?. Epidemiol Infect. 1991, 106: 523-530. 10.1017/S0950268800067583.CrossRefPubMedPubMedCentral
27.
Petersen AM, Nielsen SV, Meyer D, Ganer P, Ladefoged K: Bacterial gastroenteritis among hospitalized patients in a Danish county, 1991–93. Scand J Gastroenterol. 1996, 31: 906-911. 10.3109/00365529609052000.CrossRefPubMed
28.
Saps M, Pensabene L, Di Martino L, Staiano A, Wechsler J, Zheng X, Di Lorenzo C: Post-infectious functional gastrointestinal disorders in children. J Pediatr. 2008, 152: 812-816. 10.1016/j.jpeds.2007.11.042.CrossRefPubMed
29.
Pitkänen T, Pönkä A, Peterson T, Kosunen TU: Campylobacter enteritis in 188 hospitalized patients. Arch Intern Med. 1983, 143: 215-219. 10.1001/archinte.1983.00350020033007.CrossRefPubMed
30.
Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR: Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000, 47: 804-811. 10.1136/gut.47.6.804.CrossRefPubMedPubMedCentral
31.
Spence MJ, Moss-Morris R: The cognitive behavioral model of irritable bowel syndrome: A prospective investigation of patients with gastroenteritis. Gut. 2007, 56: 1066-1071. 10.1136/gut.2006.108811.CrossRefPubMedPubMedCentral
32.
Melby K, Dahl OP, Crisp L, Penner JL: Clinical and serological manifestations in patients during a waterborne epidemic due to Campylobacter jejuni. J Infect. 1990, 21: 309-316. 10.1016/0163-4453(90)94125-J.CrossRefPubMed
33.
Bremell T, Bjelle A, Svedhem A: Rheumatic symptoms following an outbreak of Campylobacter enteritis: A five year follow up. Ann Rheum Dis. 1991, 50: 934-938. 10.1136/ard.50.12.934.CrossRefPubMedPubMedCentral
34.
Gardner TJ, Fitzgerald C, Xavier C, Klein R, Pruckler J, Stroika S, McLaughlin JB: Outbreak of campylobacteriosis associated with consumption of raw peas. Clin Infect Dis. 2011, 53: 26-32. 10.1093/cid/cir249.CrossRefPubMed
35.
Eastmond CJ, Rennie JA, Reid TM: An outbreak of Campylobacter enteritis–a rheumatological follow up survey. J Rheumatol. 1983, 10: 107-108.PubMed
36.
McCarthy N, Andersson Y, Jormanainen V, Gustavsson O, Giesecke J: The risk of Guillain-Barré syndrome following infection with Campylobacter jejuni. Epidemiol Infect. 1999, 122: 15-17. 10.1017/S0950268898001861.CrossRefPubMedPubMedCentral
37.
Locht H, Krogfelt KA: Comparison of rheumatological and gastrointestinal symptoms after infection with Campylobacter jejuni/coli and enterotoxigenic Escherichia coli. Ann Rheum Dis. 2002, 61: 448-452. 10.1136/ard.61.5.448.CrossRefPubMedPubMedCentral
38.
Helms M, Simonsen J, Molbak K: Foodborne bacterial infection and hospitalization: A registry-based study. Clin Infect Dis. 2006, 42: 498-506. 10.1086/499813.CrossRefPubMed
39.
Kosunen TU, Ponka A, Kauranen O, Martio J, Pitkänen T, Hortling L, Aittoniemi S, Penttilä O, Koskimies S: Arthritis associated with Campylobacter jejuni/enteritis. Scand J Rheumatol. 1981, 10: 77-80. 10.3109/03009748109095276.CrossRefPubMed
40.
Ponka A, Pitkanen T, Sarna S, Kosunen TU: Infection due to Campylobacter jejuni: A report of 524 outpatients. Infection. 1984, 12: 175-178. 10.1007/BF01640893.CrossRefPubMed
41.
Schiellerup P, Krogfelt KA, Locht H: A comparison of self-reported joint symptoms following infection with different enteric pathogens: Effect of HLA-B27. J Rheumatol. 2008, 35: 480-487.PubMed
42.
Dunlop SP, Jenkins D, Neal KR, Spiller RC: Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in post infectious IBS. Gastroenterology. 2003, 125: 1651-1659. 10.1053/j.gastro.2003.09.028.CrossRefPubMed
43.
Hannu T, Mattila L, Rautelin H, Pelkonen P, Lahdenne P, Siitonen A, Leirisalo-Repo M: Campylobacter-triggered reactive arthritis: A population-based study. Rheumatology. 2002, 41: 312-318. 10.1093/rheumatology/41.3.312.CrossRefPubMed
44.
Doorduyn Y, Van Pelt W, Siezen CL, Van Der Horst F, Van Duynhoven YT, Hoebee B, Janssen R: Novel insight in the association between salmonellosis or campylobacteriosis and chronic illness, and the role of host genetics in susceptibility to these diseases. Epidemiol Infect. 2008, 136: 1225-1234.CrossRefPubMed
45.
Moss-Morris R, Spence M: To “lump” or to “split” the functional somatic syndromes: Can infectious and emotional risk factors differentiate between the onset of chronic fatigue syndrome and irritable bowel syndrome?. Psychosom Med. 2006, 68: 463-469. 10.1097/01.psy.0000221384.07521.05.CrossRefPubMed
46.
Thornley JP, Jenkins D, Neal K, Wright T, Brough J, Spiller RC: Relationship of Campylobacter toxigenicity in vitro to the development of post infectious irritable bowel syndrome. J Infect Dis. 2001, 184: 606-609. 10.1086/322845.CrossRefPubMed
47.
Townes JM, Deodhar AA, Laine ES, Smith K, Krug HE, Barkhuizen A, Thompson ME, Cieslak PR, Sobel J: Reactive arthritis following culture-confirmed infections with bacterial enteric pathogens in Minnesota and Oregon: A population-based study. Ann Rheum Dis. 2008, 67: 1689-1696. 10.1136/ard.2007.083451.CrossRefPubMed
48.
Jess T, Simonsen J, Nielsen NM, Jørgensen KT, Bager P, Ethelberg S, Frisch M: Enteric Salmonella or Campylobacter infections and the risk of inflammatory bowel disease. Gut. 2011, 60: 318-324. 10.1136/gut.2010.223396.CrossRefPubMed
49.
50.
Tam CC, Rodrigues LC, Petersen I, Islam A, Hayward A, O'Brien SJ: Incidence of Guillain-Barré syndrome among patients with Campylobacter infection: A general practice research database study. J Infect Dis. 2006, 194: 95-97. 10.1086/504294.CrossRefPubMed
51.
Schoenberg-Norio D, Mattila L, Lauhio A, Katila ML, Kaukoranta SS, Koskela M, Pajarre S, Uksila J, Eerola E, Sarna S, Rautelin H: Patient-reported complications associated with Campylobacter jejuni infection. Epidemiol Infect. 2010, 138: 1004-1011. 10.1017/S0950268809991099.CrossRef
52.
Ternhag A, Torner A, Svensson A, Ekdahl K, Giesecke J: Short- and long-term effects of bacterial gastrointestinal infections. Emerg Infect Dis. 2008, 14: 143-148. 10.3201/eid1401.070524.CrossRefPubMedPubMedCentral
53.
McCarthy N, Giesecke J: Incidence of Guillain-Barré syndrome following infection with Campylobacter jejuni. Am J Epidemiol. 2001, 153: 610-614. 10.1093/aje/153.6.610.CrossRefPubMed
54.
Hannu T, Kauppi M, Tuomala M, Laaksonen I, Klemets P, Kuusi M: Reactive arthritis following an outbreak of Campylobacter jejuni infection. J Rheumatol. 2004, 31: 528-530.PubMed
55.
Melby KK, Svendby JG, Eggebo T, Holmen LA, Andersen BM, Lind L, Sjøgren E, Kaijser B: Outbreak of Campylobacterinfection in a subarctic community. Eur J Clin Microbiol Infect Dis. 2000, 19: 542-544. 10.1007/s100960000316.CrossRefPubMed
56.
Thompson WG, Creed F, Drossman DA, Heaton KW, Mazzacca G: Functional bowel disease and functional abdominal pain. Gastroenterol Int. 1992, 5: 75-
57.
Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA: Functional bowel disorders and functional abdominal pain. Gut. 1999, 45: 43-
58.
Svedlund J, Sjodin I, Dotevall G: GSRS–a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988, 33: 129-134. 10.1007/BF01535722.CrossRefPubMed
59.
Hughes RA, Hadden RD, Gregson NA, Smith KJ: Pathogenesis of Guillain-Barré syndrome. J Neuroimmunol. 1999, 100: 74-97. 10.1016/S0165-5728(99)00195-2.CrossRefPubMed
60.
Ohman L, Simren M: Pathogenesis of IBS: Role of inflammation, immunity and neuroimmune interactions. Gastroenterol Hepatol. 2010, 7: 163-173.
61.
Townes JM: Reactive arthritis after enteric infections in the United States: The problem of definition. Clin Infect Dis. 2010, 50: 247-254. 10.1086/649540.CrossRefPubMed
62.
World Health Organization: International classification of Diseases. 2012
63.
Withington SG, Chambers ST: The cost of campylobacteriosis in New Zealand in 1995. N Z Med J. 1997, 110: 222-224.PubMed
64.
Mangen MJ, Havelaar AH, Bernsen R, Van Koningsveld R, De Wit GA: The costs of human Campylobacter infections and sequelae in the Netherlands: A DALY and cost-of-illness approach. Food Econ. 2005, 2: 35-51.
65.
Ruzante JM, Majowicz SE, Fazil A, Davidson VJ: Hospitalization and deaths for select enteric illnesses and associated sequelae in Canada, 2001–2004. Epidemiol Infect. 2011, 139: 937-945. 10.1017/S0950268810001883.CrossRefPubMed
66.
Borenstein M, Hedges LV, Higgins JPT, Rothstein HR: Introduction to meta-analysis. 2009, John Wiley and Sons, Ltd: United KingdomCrossRef
Metadata
Title
Systematic review and meta-analysis of the proportion of Campylobacter cases that develop chronic sequelae
Authors
Jessica Keithlin
Jan Sargeant
M Kate Thomas
Aamir Fazil
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2014
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/1471-2458-14-1203

Other articles of this Issue 1/2014

BMC Public Health 1/2014 Go to the issue

Research article

Predictors of long-term change of a physical activity promotion programme in primary care

Research article

Public knowledge and preventive behavior during a large-scale Salmonella outbreak: results from an online survey in the Netherlands

Study protocol

On your feet: protocol for a randomized controlled trial to compare the effects of pole walking and regular walking on physical and psychosocial health in older adults

Research article

Trends in television time, non-gaming PC use and moderate-to-vigorous physical activity among German adolescents 2002–2010

Research article

Patients’ perspectives of care for type 2 diabetes in Bangladesh –a qualitative study

Research article

Knowledge and acceptability of Chlamydia trachomatis screening among pregnant women and their partners; a cross-sectional study